Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities
13.7.2021 14:30:00 EEST | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005391/en/
Integrity Bio is known in the biopharmaceutical industry as experts in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled its manufacturing capacity. Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.
Integrity Bio’s biologic capabilities are complementary with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
About Integrity Bio
Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries. The organization is known for overcoming challenges associated with biologic formulations and for accommodating unique manufacturing requirements for preclinical and clinical development. For more information, please visit IntegrityBio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005391/en/
Contact information
Corporate:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Adds Collaborating Firm TechSparq22.10.2026 16:30:00 EEST | Press release
Andersen Consulting broadens its technology and business transformation capabilities through a Collaboration Agreement with TechSparq, a U.S.-based firm that combines strategy, commerce engineering, and AI with hands-on implementation. TechSparq is a digital consulting firm providing strategy and advisory, commerce engineering, and AI and agentic commerce services to organizations across retail and consumer goods, luxury and fashion, and eCommerce and direct-to-consumer markets. Headquartered in Oregon, the firm combines strategic planning with hands-on delivery to help clients advance digital initiatives, customer experience, and operating models. “We built our firm to close the gap between the people who develop the strategy and the people responsible for making it work,” said Dedrick Boyd, founder and CEO of TechSparq. “Our collaboration with Andersen Consulting gives us an opportunity to bring that execution-focused model to a broader range of organizations while combining our appr
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age22.10.2026 16:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022474590/en/ SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TOKYO: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cell Pro Japan Co., Ltd. (together, the “Waqoo Group”). The test aims to provide insight into an individual’s physical condition that chro
Lenovo Expands AI Library with Proven, Validated Use Cases to Accelerate Business Outcomes and Drive Greater Value Per Token22.10.2026 16:00:00 EEST | Press release
Lenovo today expanded the Lenovo AI Library with new, validated AI use cases, extending its portfolio of enterprise-ready solutions that can help organizations move from AI experimentation to measurable business outcomes up to 24x faster1 than custom-built implementations. Now available through the Lenovo AI Library, the added use cases provide proven starting points to accelerate AI deployments and realize returns from investments sooner. Alongside the expansion, new research conducted by The Futurum Group and Signal65 validates how Lenovo’s AI Library, infrastructure and services can help enterprises optimize AI economics for greater value per token as deployments scale. Lenovo’s AI Library additions address high-impact enterprise and industry use cases, helping organizations boost workforce productivity, modernize IT operations, elevate customer service, and turn operational data into actionable intelligence: Lenovo AI Computer Vision for Retailtransforms video and operational data
Follow-on Order Brings Orders from INNIO Data Center Customer to 1.72 GW, Further Strengthening INNIO’s Data Center Backlog and Revenue Visibility22.10.2026 15:30:00 EEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced a 620 megawatt (MW) follow-on order from a leading developer and operator of mega-scale data center campuses in the U.S. Together with the customer’s 1.1 gigawatt (GW) order announced in July 2026, the new order brings cumulative orders from the customer to approximately 1.72 GW, further strengthening INNIO’s order backlog and visibility into future revenues. “This follow-on order, coming just months after the customer’s initial 1.1 GW order, underscores the strength of customer demand and continued confidence in INNIO. Our containerized Jenbacher solutions deliver what data centers need most: fast deployment, high power density, fuel efficiency, and the performance to support demanding AI workloads,” said Dr. Olaf Berlien, President and CEO of INNIO. “Repeat orders of this scale, combined with long-term service agreements, strengthen our backlog and expand the services base that underpins our business model,” added Dr. Berlien. All 620 MW will
European Public Transport Budgets Require 36% Annual Spending Increase by 2035, Arthur D. Little and Polis Research Finds22.10.2026 15:30:00 EEST | Press release
Europe’s public transport sector currently accounts for €130 billion in annual expenditure, yet faces a growing funding gap as demand rises and environmental and resilience requirements intensify. New research from Arthur D. Little (ADL)’s Future of Mobility Lab and POLIS, a network of European cities and regions collaborating to develop innovative and sustainable urban transport solutions, outlines the scale of this financial shortfall and provides radical recommendations for overcoming it. Based on research with senior transport and policymakers, in-depth literature reviews, and real-world data from Paris, London, Amsterdam, Berlin and New York, the report estimates that additional spending will require a 36% increase in overall annual expenditure from now to 2035 onwards. This is made up of a 13% rise in operating expenditure (OPEX) and 56% in capital expenditure (CAPEX), driven by: Hidden debt caused by historic underinvestment in existing infrastructure (6% of additional funding n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom